Waltham-based Nano Dimension is looking to swap its 3D printers for DNA data. The company said Monday it has signed a non-binding term sheet to combine with Infinite Epigenetics in a stock-for-stock reverse merger that pegs the epigenetics outfit at roughly $890 million. If it closes as sketched out, Infinite would land a Nasdaq listing and tap more than $400 million in cash at closing, while current Nano shareholders would keep a meaningful minority stake. It is a sharp turn for a company once best known for 3D-printing and electronics-manufacturing systems.
According to a press release via GlobeNewswire, the deal outline envisions a reverse-triangular merger or a similar structure. The combined business would operate under the Infinite Epigenetics name and seek the Nasdaq ticker IEAI. The companies stress that the term sheet is non-binding and that the merger still depends on negotiating definitive agreements, meeting customary closing conditions and winning shareholder approval. Nano CEO David Stehlin, quoted in the release, said Infinite was picked after a multi-month strategic review and called it "a category-defining company."
From printers to preventive health
The potential merger sits on top of a fast reset at Nano following a burst of acquisitions and restructuring over the past year. Nano's public filings recap its 2024-25 deal spree and balance-sheet moves, including purchases tied to Desktop Metal and Markforged, along with efforts to cash out of legacy assets as part of a broader overhaul. Local coverage by the Boston Business Journal has followed how the Waltham leadership team handled that strategic review, while trade outlets have chronicled how those earlier transactions reshaped the company.
What Infinite brings
The deal marketing materials frame Infinite Epigenetics as an AI-driven diagnostics platform that includes TruDiagnostic and Tally Health and holds what it describes as one of the largest private DNA-methylation datasets in the market, with more than 120,000 samples collected since 2020. "Our mission is to help move healthcare from reactive to proactive by giving clinicians and individuals earlier insight into what the body is signaling," Infinite CEO Dr. Matthew Dawson said in the release. The combined company would aim at earlier disease detection and risk forecasting, using what the parties describe as a biological AI foundation model.
Board math and shareholder mechanics
The term sheet also lays out the basic ownership and governance picture if a deal is finalized. Infinite is valued at about $890 million, and Nano's exchange ratio would be calculated off a stated value equal to its net cash plus a 20% premium, so Infinite holders could end up with majority control depending on the final numbers. The outline further calls for contingent value rights for Nano shareholders of record before closing, tied to whatever proceeds Nano generates from selling its legacy assets, and a seven-member board on which Infinite would name multiple directors, according to Nano's Form 8-K filed with the SEC. The term sheet gives the parties a 30-day exclusivity period to negotiate and contemplates a definitive agreement and shareholder vote later this summer.
Next steps
Under the tentative timeline, Nano and Infinite plan to hammer out and sign a definitive merger agreement by July 31, then convene an extraordinary general meeting of Nano shareholders to vote on the transaction, with closing targeted for later in the year. The companies have already held a conference call and released an investor presentation with additional detail, with both sets of materials available through Nano's investor relations site and as exhibits in its SEC filings. Investors will be watching the proxy documents closely, along with how much cash Nano ultimately pulls from its legacy-asset sales compared with the expectations baked into the term sheet.
For Waltham and the surrounding tech cluster, the proposed tie-up would turn a once hardware-heavy name into a data-centric health diagnostics play, and it raises the usual local questions about strategy, headcount and where the center of gravity lands if the deal closes. Expect more specifics to surface in the coming weeks as proxy statements, updated presentations and additional filings spell out the fine print and the cash math.
